GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments.

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Alcohol use is also linked to cognitive decline, and a recent study published in the journal Neurology found that consuming a ...

Q1 2025 Management View CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney ...

Discover a study that has proposed a predictive model for cirrhosis and hepatocellular carcinoma in individuals with ...

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial. The Fox Medical Team's Dr. Mike Cirigliano joined Good Day to take a look ...

(Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Liver diseases on the rise in kids? Understand the symptoms and preventive measures to safeguard your child's health. Get ...

Walnuts, brazil nuts, and almonds are rich in omega-3 fatty acids and vitamin E, both of which help reduce oxidative stress ...